Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration
Authors
Keywords
-
Journal
BRAIN
Volume 144, Issue 12, Pages 3674-3691
Publisher
Oxford University Press (OUP)
Online
2021-09-23
DOI
10.1093/brain/awab356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment
- (2020) Md. Razaul Karim et al. Molecular Neurodegeneration
- ZNF746/PARIS overexpression induces cellular senescence through FoxO1/p21 axis activation in myoblasts
- (2020) Ju-Hyeon Bae et al. Cell Death & Disease
- Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s disease
- (2019) Saurav Brahmachari et al. BRAIN
- PARIS reprograms glucose metabolism by HIF-1α induction in dopaminergic neurodegeneration
- (2018) Hojin Kang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
- (2018) Saebom Lee et al. HUMAN MOLECULAR GENETICS
- PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival
- (2017) Yunjong Lee et al. Cell Reports
- c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
- (2017) Saurav Brahmachari et al. Journal of Parkinsons Disease
- TRIM28 and Interacting KRAB-ZNFs Control Self-Renewal of Human Pluripotent Stem Cells through Epigenetic Repression of Pro-differentiation Genes
- (2017) Urszula Oleksiewicz et al. Stem Cell Reports
- LIN28A enhances the therapeutic potential of cultured neural stem cells in a Parkinson’s disease model
- (2016) Yong-Hee Rhee et al. BRAIN
- Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration
- (2016) Saurav Brahmachari et al. JOURNAL OF CLINICAL INVESTIGATION
- The Capable ABL: What Is Its Biological Function?
- (2014) J. Y. J. Wang MOLECULAR AND CELLULAR BIOLOGY
- The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
- (2014) Senthilkumar S. Karuppagounder et al. Scientific Reports
- Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model
- (2013) Syed Z. Imam et al. PLoS One
- Programmed Cell Death in Parkinson's Disease
- (2013) K. Venderova et al. Cold Spring Harbor Perspectives in Medicine
- Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue
- (2012) A. Galmozzi et al. DIABETES
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
- (2011) Joo-Ho Shin et al. CELL
- Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease
- (2011) S. Z. Imam et al. JOURNAL OF NEUROSCIENCE
- Puzzling over MDM4–p53 network
- (2010) F. Mancini et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
- (2010) H. S. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modes of p53 Regulation
- (2009) Jan-Philipp Kruse et al. CELL
- SnapShot: p53 Posttranslational Modifications
- (2008) Jan-Philipp Kruse et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation